MLPH.US Molecular Pharmacology (USA) Ltd
- Market cap
- USD 404K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is MLPH.US undervalued?
Graham numberThe Graham number of Molecular Pharmacology (USA) Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Molecular Pharmacology (USA) Ltd fundamental analysis
No fundamental analysis for Molecular Pharmacology (USA) Ltd yet.
Molecular Pharmacology (USA) Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Molecular Pharmacology (USA) Ltd
AI Energy Inc., a development stage company, focuses on discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL (tripeptofen) compound. The company was formerly known as Molecular Pharmacology (USA), Ltd. and changed its name to AI Energy Inc. in April 2026. The company is based in Shanghai, China.
Full company profileMolecular Pharmacology (USA) Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Molecular Pharmacology (USA) Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2007 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Gross Profit | -1.54K | - | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - |
| Operating Income | -566K | -118K | -117K | -122K | -179K | -209K | -117K | -8.00K | -13.3K | -5.52K | -2.40K |
| EBITDA | -564K | -117K | -116K | -121K | -179K | -209K | -117K | -8.00K | -901K | -5.52K | -2.40K |
| Net Income | -566K | -94.3K | -117K | -122K | -179K | -210K | -117K | -8.00K | -901K | -5.52K | -2.40K |
| EPS | -0.22 | -0.04 | -0.05 | -0.05 | -0.08 | -0.09 | -0.05 | 0.00 | -0.05 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 47.5K | 13.4K | 11.7K | 16.9K | 8.84K | 12.3K | 8.97K | - | - | - | - |
| Total Liabilities | 1.36M | 1.30M | 1.50M | 1.98M | 2.09M | 2.07M | 2.24M | - | - | - | - |
| Shareholders' Equity | -1.31M | -1.29M | -1.49M | -1.97M | -2.08M | -2.05M | -2.23M | - | - | - | - |
| Cash & Short-term Investments | 21.0K | 7.54K | 7.98K | 8.68K | 2.57K | 7.05K | 2.38K | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -459K | -75.2K | -125K | -127K | -178K | -206K | -105K | - | - | - | -129K |
| Capital Expenditure | 731.00 | 114.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | 0.00 |
| Free Cash Flow | -460K | -75.3K | -125K | -127K | -178K | -206K | -105K | - | - | - | -129K |
| Ratios | |||||||||||
| ROA | -1,191.8% | -705.1% | -1,006.0% | -721.5% | -2,029.0% | -1,712.6% | -1,303.8% | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Molecular Pharmacology (USA) Ltd dividends
Molecular Pharmacology (USA) Ltd has not paid dividends in the last 8 fiscal years.
Last stock split: 1:50 on Jun 18, 2026.
Who owns Molecular Pharmacology (USA) Ltd
Ownership data of Molecular Pharmacology (USA) Ltd is not available yet.
Molecular Pharmacology (USA) Ltd company profile
- Company name
- Molecular Pharmacology (USA) Ltd
- Ticker
- MLPH.US
- Exchange
- USA Stocks
- Sector
- Financial Services
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 1868 Gonghe Xin Road, Shanghai, China, 200072
- Phone
- 86 13 6416 17929
- Website
- -
About Molecular Pharmacology (USA) Ltd
AI Energy Inc., a development stage company, focuses on discovery and development of analgesic and anti-inflammatory products based on the proprietary MPL-TL (tripeptofen) compound. The company was formerly known as Molecular Pharmacology (USA), Ltd. and changed its name to AI Energy Inc. in April 2026. The company is based in Shanghai, China.
Molecular Pharmacology (USA) Ltd management
1- Mr. Jeffrey David EdwardsCEO, President, CFO & Director · born 1951